Posters

Aflibercept intravitreal injection for myopic choroidal neovascularization

Poster Details

First Author: J.Nassaralla BRAZIL

Co Author(s):                                 

Abstract Details



Purpose:

To evaluate the clinical results of Eylea®® (aflibercept) intravitreal injection (RII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).

Setting:

Anti-angiogenic update

Methods:

20 patients with subfoveal PM-CNV, were treated with of 2 mg ( 50microliters) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. RII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 3 years.

Results:

The mean age of the study patients was 28 years (21-37) and the mean refractive error -11.25 D. At 36 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/50 (20/200-20/30). Only 3 patients lost 35 letters due to macular atrophy; the other 7 increased or stabilized their VA. Mean macular thickness decreased from 352 to 230 µm. No ocular or general side effects were recorded.

Conclusions:

These short-term results suggest that RII are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy